Parathyroid hormone
- Generic Name
- Parathyroid hormone
- Brand Names
- Natpara, Natpar
- Drug Type
- Biotech
- CAS Number
- 9002-64-6
- Unique Ingredient Identifier
- N19A0T0E5J
- Background
Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa).
Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).
- Indication
For use/treatment in osteoporosis.
- Associated Conditions
- Hypocalcemia, Hypoparathyroidism
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2011-03-23
- Last Posted Date
- 2013-03-01
- Lead Sponsor
- Unigene Laboratories Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT01321723
- Locations
- 🇪🇪
CCBR, Tallinn, Estonia
A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Shire
- Target Recruit Count
- 51
- Registration Number
- NCT01297309
- Locations
- 🇺🇸
Michigan Bone & Mineral Clinic PC, Detroit, Michigan, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸The Vancouver Clinic, Vancouver, Washington, United States
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 42
- Registration Number
- NCT01268098
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Michigan Bone & Mineral Clinic PC, Detroit, Michigan, United States
HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 62
- Registration Number
- NCT01199614
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Use of NPSP558 in the Treatment of Hypoparathyroidism
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 124
- Registration Number
- NCT00732615
- Locations
- 🇺🇸
Mayo Clinic-Scottsdale, Scottsdale, Arizona, United States
🇺🇸Advance Medical Research LLC, Lakewood, California, United States
🇺🇸Diabetes Associates, Orange, California, United States
PTH & Ibandronate Combination Study (PICS)
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 44
- Registration Number
- NCT00683163
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2008-08-19
- Lead Sponsor
- Manhattan Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT00593177
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Minnesota Clinical Study Center, Fridley, Minnesota, United States
🇺🇸Advanced Dermatology and Cosmetic Surgery, Ormond Beach, Florida, United States
Bone Properties in Hypoparathyroidism: Effects of PTH
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- John P. Bilezikian
- Target Recruit Count
- 68
- Registration Number
- NCT00473265
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 60
- Registration Number
- NCT00221299
- Locations
- 🇺🇸
UC Davis General Medicine Research Clinic, Sacramento, California, United States
Open Label Extension
- Conditions
- Osteoporosis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Shire
- Target Recruit Count
- 91
- Registration Number
- NCT00172120
- Locations
- 🇺🇸
'The University of Chicago, Chicago, Illinois, United States
🇺🇸'Rapid City Medical Center, Rapid City, South Dakota, United States
🇦🇷'IDIM, Buenos Aires, BUE, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.